Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of buprenorphine transdermal patches in healthy Chinese adults
ChiCTR2400090209Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buprenorphine in chronic pain (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Cmax, AUC0-t and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
buprenorphine
03
Conditions
chronic pain
Beyond the preview
Go deeper on ChiCTR2400090209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090209.